Search Results - "Kawata, Kazuhito"

Clinical Outcome of Endoscopic Transpapillary Drainage for Biliary Obstruction Due to Non-Hepato-Pancreato-Biliary Cancer: A Two-Center Retrospective Cohort Study.

Authors: Kitsugi, Kensuke Kawata, Kazuhito Hosoda, Yoshisuke et al.

Source: Clinics & Practice. Feb2026, Vol. 16 Issue 2, p24. 15p.

Three‐Year Long‐Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice.

Authors: Ohama, Hideko Hiraoka, Atsushi Tada, Toshifumi et al.

Source: Cancer Medicine. Feb2026, Vol. 15 Issue 2, p1-10. 10p.

Tips for Hepatologist Referral of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease with Alanine Aminotransferase Levels ≤ 30 U/L.

Authors: Kawanaka, Miwa Fujii, Hideki Iwaki, Michihiro et al.

Source: Diagnostics (2075-4418). Jul2025, Vol. 15 Issue 13, p1591. 10p.

Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice.

Authors: Hiraoka, Atsushi Tada, Toshifumi Hirooka, Masashi et al.

Source: Hepatology Research. Mar2025, Vol. 55 Issue 3, p444-453. 10p.

Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma.

Authors: Naganuma, Atsushi Kakizaki, Satoru Hiraoka, Atsushi et al.

Source: Cancer Medicine. Jan2025, Vol. 14 Issue 2, p1-10. 10p.

The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis.

Authors: Kawata, Kazuhito Joshita, Satoru Shimoda, Shinji et al.

Source: Hepatology Research. Jan2021, Vol. 51 Issue 1, p80-89. 10p.

Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation.

Authors: Kitsugi, Kensuke Kawata, Kazuhito Noritake, Hidenao et al.

Source: Journal of Clinical Medicine. Mar2023, Vol. 12 Issue 6, p2210. 14p.

Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients.

Authors: Hatanaka, Takeshi Kakizaki, Satoru Hiraoka, Atsushi et al.

Source: Alimentary Pharmacology & Therapeutics. Nov2024, Vol. 60 Issue 10, p1361-1373. 13p.

Validation study of age‐independent fibrosis score (Fibrosis‐3 index) in patients with metabolic dysfunction‐associated steatotic liver disease.

Authors: Nouso, Kazuhiro Kawanaka, Miwa Fujii, Hideki et al.

Source: Hepatology Research. Oct2024, Vol. 54 Issue 10, p912-920. 9p.

Association Between Laboratory Values and Covert Hepatic Encephalopathy in Patients with Liver Cirrhosis: A Multicenter, Retrospective Study.

Authors: Koyano, Kaori Atsukawa, Masanori Tsubota, Akihito et al.

Source: Journal of Clinical Medicine. Mar2025, Vol. 14 Issue 6, p1858. 13p.

This result is not displayed to guests.
Login for full access.

Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.

Authors: Tada, Toshifumi Kumada, Takashi Hiraoka, Atsushi et al.

Source: Alimentary Pharmacology & Therapeutics. Jul2024, Vol. 60 Issue 2, p233-245. 13p.

Safety and effectiveness of SARS‐CoV‐2 vaccines for patients with intractable hepatobiliary diseases: A multicenter, questionnaire‐based, cross‐sectional study.

Authors: Tanifuji, Ayaka Ohfuji, Satoko Matsumoto, Kosuke et al.

Source: Hepatology Research. Jul2024, Vol. 54 Issue 7, p706-715. 10p.

Multicenter, retrospective, cohort study shows platelet counts predict hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease.

Authors: Fujii, Hideki Fujii, Makoto Iwaki, Michihiro et al.

Source: Hepatology Research. May2023, Vol. 53 Issue 5, p391-400. 10p.

Hepatic inflammation and fibrosis are profiles related to mid‐term mortality in biopsy‐proven MASLD: A multicenter study in Japan.

Authors: Tsutsumi, Tsubasa Kawaguchi, Takumi Fujii, Hideki et al.

Source: Alimentary Pharmacology & Therapeutics. Jun2024, Vol. 59 Issue 12, p1559-1570. 12p.

Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease.

Authors: Oeda, Satoshi Seko, Yuya Hayashi, Hideki et al.

Source: Hepatology Research. Jun2023, Vol. 53 Issue 6, p489-496. 8p.

A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis.

Authors: Yagi, Minami Matsumoto, Kosuke Komori, Atsumasa et al.

Source: Liver International. Aug2020, Vol. 40 Issue 8, p1926-1933. 8p. 2 Charts, 4 Graphs.

Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis‐related fibrosis: Multicenter study.

Authors: Seko, Yuya Takahashi, Hirokazu Toyoda, Hidenori et al.

Source: Hepatology Research. Apr2023, Vol. 53 Issue 4, p312-321. 10p.

C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.

Authors: Tada, Toshifumi Kumada, Takashi Hiraoka, Atsushi et al.

Source: Scientific Reports. 5/19/2022, Vol. 12 Issue 1, p1-10. 10p.

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study.

Authors: Hiraoka, Atsushi Kumada, Takashi Tada, Toshifumi et al.

Source: Scientific Reports. 8/17/2021, Vol. 11 Issue 1, p1-11. 11p.